Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
26 hedge funds and large institutions have $14.2M invested in Regulus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
15,167% more call options, than puts
Call options by funds: $458K | Put options by funds: $3K
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
4% more funds holding
Funds holding: 25 → 26 (+1)
1% less ownership
Funds ownership: 55.97% → 54.97% (-1%)
5% less capital invested
Capital invested by funds: $15M → $14.2M (-$783K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$51.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.3K |
| 3 |
Renaissance Technologies
New York
|
+$5.99K |
| 4 |
Citigroup
New York
|
+$2.83K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$36K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.75K |
| 3 |
GC
Grimes & Company
Westborough,
Massachusetts
|
-$169 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$85 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$68 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Osaic Holdings
Scottsdale,
Arizona
| – | -$68 | -50 | Closed |
|
RGLS Hedge Fund Activity: Q4 2023 in Review
26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2023, worth a combined $14.2M — down 5.2% from $15M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RGLS positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $51.3K. The largest seller was Virtu Financial, exiting entirely with an estimated $36K sold.
- 26 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2023, up from 25 in Q3 2023.
- Funds reported $14.2M of Regulus Therapeutics stock for Q4 2023, down 5.2% quarter-over-quarter.
- 3 funds opened new Regulus Therapeutics positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q4 2023 was Victory Capital Management, an estimated $51.3K added.
- The largest Regulus Therapeutics seller in Q4 2023 was Virtu Financial, an estimated $36K sold.
Based on aggregated 13F filings for Q4 2023.